IDWeek and HIV Glasgow 2016*

October 23-30, 2016; Glasgow, United Kingdom; New Orleans, Louisiana
Review the clinical impact of new HIV-related data presented at 2 scientific meetings in the fall of 2016: IDWeek and HIV Glasgow. This program includes Capsule Summaries, downloadable slidesets, and an expert analysis text module.

Clinical Impact


Previous DRV dose and baseline genotypic susceptibility score did not negatively affect the efficacy of switching from DRV-containing ART to EVG/COBI/TAF/FTC plus DRV.

Released: November 8, 2016

Switch to RPV/FTC/TAF from NNRTI/FTC/TDF-containing regimen associated with significant improvements in markers of renal and bone safety.

Released: November 10, 2016

Efficacy and safety outcomes were independent of third agent and at Week 48 were consistent in patients 50 years of age or older.

Released: November 17, 2016

Discontinuation for neuropsychiatric events more common for dolutegravir and comprised primarily sleep disturbances and insomnia; women, older adults, and patients initiating concurrent abacavir at increased risk.

Released: November 8, 2016

After 48 weeks, switch to DRV/RTV plus 3TC from DRV/RTV plus TDF/FTC or ABC/3TC was well tolerated and associated with maintenance of virologic suppression without emergent resistance.

Released: November 16, 2016

Four of 85 patients completing 24 weeks of dolutegravir treatment experienced virologic failure.

Released: November 17, 2016

Similar virologic efficacy observed across disease and demographic subgroups.

Released: November 16, 2016

Both regimens demonstrated high genetic barriers to resistance.

Released: November 23, 2016

Low rates of psychiatric adverse events in DTG/ABC/3TC and ATV/RTV plus TDF/FTC treatment arms.

Released: November 17, 2016

Insomnia was the most common dolutegravir-related psychiatric adverse event in all 4 examined trials.

Released: November 10, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?